Rapt Therapeutics Inc's Customers Performance

Name: Rapt Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

RAPT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


RAPT's Source of Revenues		• List of RAPT Customers

for the same period Rapt Therapeutics Inc

• List of RAPT Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Rapt Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Rapt Therapeutics Inc Contracts

RAPT Therapeutics to Announce Phase 2 Trial Results for RPT904 in Chronic Spontaneous Urticaria

RAPT Therapeutics, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, is poised to release topline data from its Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) on October 20, 2025. The trial has been conducted in partnership with Shanghai Jeyou Pharmaceutical Co., Ltd., formerly known as Shanghai Jemincare Pharmaceutical Co., Ltd.Chronic Spontaneous Urticaria is characterized by the spontaneous appearance of hives, accompanied by intense itching, and can significantly impair quality of life in affected individuals. Current therapeutic options for CSU often have varying degrees of efficacy and potential side effects, underscoring the...

In a groundbreaking development, RAPT Therapeutics has announced highly promising results from its phase 2 trial involving Tivumecirnon in combination with anti-PD-1 immunotherapy. The study focused on patients with head and neck cancer who had prior experience with CPI (checkpoint inhibitors) treatments. The findings have unveiled a significant breakthrough in the treatment of this challenging ...

Revealing Tivumecirnon s Potential: Groundbreaking Phase 2 Trial Demonstrates Impressive Response Rate in CPI-Experienced Head and Neck Cancer Patients, Regardless of PD-L1 or HPV StatusIn a groundbreaking development, RAPT Therapeutics has announced highly promising results from its phase 2 trial involving Tivumecirnon in combination with anti-PD-1 immunotherapy. The study focused on patients with head and neck cancer who had prior experience with CPI (checkpoint inhibitors) treatments. The findings have unveiled a significant breakthrough in the treatment of this challenging form of cancer, offering hope to patients worldwide.The trial has yielded a confirmed response rate (ORR) of 15.6% among all partici...

RAPT Therapeutics Faces Investor Investigation for Potential Securities Law Violations

As reported on March 11, 2024, prominent stockholder rights law firm Bragar Eagel and Squire, P.C. announced its investigation into RAPT Therapeutics, Inc. (NASDAQ: RAPT) on behalf of the company s stockholders. The law firm s probe aims to determine if RAPT has contravened federal securities laws or participated in any other unlawful business practices. This development adds uncertainty to the future of the company, raising concerns among investors.RAPT Therapeutics is a biopharmaceutical firm focusing on developing innovative immunology-based therapies for patients with significant unmet medical needs. The investigation initiated by Bragar Eagel and Squire brings potential legal ramifications, which could ...

RAPT's Stock Performance relative to it's Customers

RAPT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Rapt Therapeutics Inc	1,563.32	3.25	-105.64	42
SUBTOTAL	0.00	0.00	0.00	-

Sources: Rapt Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Rapt Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Rapt Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.